Cepheid Places 125 GeneXperts in Q3, Sees First Impact of PCR Royalty Expirations on Bottom Line

The company's third-quarter financial report shows "the first benefits from the phase-out of the very heavy royalty burden that we have carried since the launch of the GeneXpert back in 2006," said Cepheid CEO John Bishop.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.